AdvaMed® Comment Letter to FDA: Exemptions from Premarket Notification Requirements for Class II Devices
AdvaMed’s® comments on FDA’s 510(k) exemption framework for Class II devices and its impact on innovation and patient access.
Resource Library
Access our full library of guidance, white papers, and other resources developed by and for the medical technology industry.
Filter By:
2025 Annual Report
Explore AdvaMed®’s key achievements and milestones in 2025 on behalf of our member companies and the patients they serve.
AdvaMed® 2025 Membership Has Its Privileges: Advocacy Wins for Medtech Members
AdvaMed® 2025 Membership Has Its Privileges highlights major legislative and regulatory wins delivering millions in savings and new revenue for members.
Scott Whitaker Op-Ed: Medicare must keep pace with FDA-authorized breakthrough medical technologies
Medicare breakthrough medical technologies face delays between FDA authorization and coverage decisions, slowing patient access to innovation.
AdvaMed® Comment Letter to ASTP/ONC: Accelerating AI Adoption in Clinical Care
AdvaMed’s® Comment Letter to ASTP/ONC, outlines concrete policy reforms across FDA oversight, CMS payment pathways, and HIPAA data-sharing rules to accelerate patient access to AI-enabled medical technologies. As AI-enabled medical…
Listen to AdvaMed®'s Podcast
Brought to you by AdvaMed®, Medtech POV with Scott Whitaker is a podcast that covers the intersection of medtech and policy from every perspective.
AdvaMed® 2026 State Policy Briefing Series
Explore the 2026 State Policy Briefing Series for insights on medtech policy, legislative activity, and regulatory updates impacting the medtech industry.
AdvaMed® Comment Letter to OIG’s Annual Solicitation for Safe Harbors and Special Fraud Alerts
AdvaMed® comment letter to the OIG’s recommends updates to safe harbors, value-based arrangements, & oversight to support value-driven healthcare.
AdvaMed® Plays Tariff Chess, Trump Plays Checkers
As tariff uncertainty continues in 2025,AdvaMed® plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.
AdvaMed® Advancements: Q4 2025 Report
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.